论文部分内容阅读
目的研究慈菇消脂胶囊对非酒精性脂肪性肝病(NAFLD)大鼠谷胱甘肽过氧化酶2(GSH-PX2)、固醇元件结合蛋白-1c(SREBP-1c mRNA)基因表达的影响,探讨其作用机制。方法用高脂饲料喂食的方法复制非酒精性脂肪肝模型。随机分为正常组、模型组、慈菇消脂胶囊高剂量组、慈菇消脂胶囊中剂量组、慈菇消脂胶囊低剂量组、吡格列酮药物阳性对照组。慈菇消脂胶囊对模型大鼠治疗6周后,观察模型大鼠肝组织病理形态学变化;血清血脂(TC、TG、SF)、碱性磷酸酶(AKP)、脂蛋白脂酶(LPL)、肝脂酶(HL)变化以及GSH-PX2和SREBP-1c mRNA表达。结果模型组大鼠肝小叶内出现大量脂肪变性,汇管区伴有炎细胞浸润以及部分点状肝细胞坏死,治疗前与正常组比较,模型组大鼠TC、TG、SF均升高,GSH-PX2表达减少、SREBP-1c mRNA增多。治疗后与模型组比较,慈菇消脂胶囊各剂量组,肝脏脂肪变性和炎症均有不同程度的减轻。慈菇消脂胶囊能降低模型大鼠TC、TG、SF含量,降低AKP、提升HL、LPL水平(P<0.05);对GSH-PX2、SREBP-1c mRNA表达有较好调节作用(P<0.05-0.01)。结论慈菇消脂胶囊具有改善肝功能,调节肝脂代谢,调节GSH-PX2、SREBP-1c mRNA表达,减轻肝细胞脂肪变性,从而起到对非酒精性脂肪性肝病的治疗作用。
Objective To study the effect of Zijie Xiaozhi capsule on the gene expression of glutathione peroxidase 2 (GSH-PX2) and steroid element binding protein-1c (SREBP-1c mRNA) in non-alcoholic fatty liver disease (NAFLD) , To explore its mechanism of action. Methods The non-alcoholic fatty liver model was reproduced by feeding with high fat diet. The rats were randomly divided into normal group, model group, high dose group of Zijinzhizhi capsule, middle dose of Zijinzhizhi Capsule, low dose of Zijinzhizhi Capsule and pioglitazone positive control group. After treated for 6 weeks, the effect of Zijin Xiaozhi Capsule on pathological changes of liver in model rats was observed. Serum lipids (TC, TG, SF), alkaline phosphatase (AKP), lipoprotein lipase (LPL) , Hepatic lipase (HL) changes and GSH-PX2 and SREBP-1c mRNA expression. Results In the model group, a large number of steatosis occurred in the hepatic lobule, inflammatory cell infiltration and some punctate hepatocyte necrosis in the portal area were observed. Compared with the normal group, TC, TG and SF in the untreated group increased and GSH- PX2 expression decreased, SREBP-1c mRNA increased. After treatment with the model group, Sagitailiazhi capsule dose groups, hepatic steatosis and inflammation were reduced to varying degrees. Zijie Xiaozhi Capsule can reduce the contents of TC, TG, SF, AKP, HL and LPL in model rats (P <0.05), and regulate the expressions of GSH-PX2 and SREBP-1c mRNA -0.01). Conclusion Zijie Xiaozhi capsule can improve the liver function, regulate hepatic lipid metabolism, regulate the expression of GSH-PX2 and SREBP-1c mRNA, and reduce the fatty degeneration of hepatocytes, thus playing a therapeutic role in non-alcoholic fatty liver disease.